肝癌根治性切除术后免疫治疗联合肝动脉化疗栓塞的临床研究

目的 研究肝癌根治性切除术后免疫治疗联合肝动脉化疗栓塞的价值。材料与方法 肝癌根治性切除者80例，随机分为两组。肝癌根治性切除术后免疫治疗联合肝动脉化疗栓塞40例为观察组；肝癌根治性切除术后单纯免疫治疗40例为对照组。对两组病例1年、2年的肝内复发率和生存率分别作x^2检验，进行对照分析。结果 观察组１年、２年的肝内复发率分别为１２．５％（5／40）、30．0％（12／40），较对照组32．5％（13／40）、52．5％（21／40）降低（x^2值分别为4．59、4．18，P值均＜0．05）；观察组1年、2年的生存率分别为85．0％（34／40）、70．0％（28／40），较对照组65．0％（26／40）、47．5％（19／40）提高（x^2值分别为4．27、4．18，P值均＜0．05）。结论 肝癌根治性切除术后免疫治疗联合肝动脉化疗栓塞是控制肝内复发率，提高患者生存率的有价值的治疗方法。

Clinical Study of Immunotherapy Combined with Hepatic Chemoembolization for Liver Cancer after Radical Surgery

Objective　To evaluate immunotherapy combined with hepatic chemoembolization in the treatment of liver cancer after radical operation.　Materials and Methods　Eighty patients who had received radical operation for liver cancer were equally divided into two groups: (1) study group, receiving immunotherapy together with hepatic chemoembolization; (2) control group, receiving immunotherapy only. Intrahepatic recurrence rate and survival rate at one and 2 years after the treatment in both groups were analyzed and compared by using χ2 testing. 　Results　The intrahepatic recurrence rate (and the survival rate) at one and 2 years of the study group and control group was 12.5%, 30.0% (85.0%, 70.0%) and 32.5%, 52.5% (65.0%, 47.5%), with the χ2 value of 4.59 and 4.18 (4.27 and 4.18)), respectively (P＜0.05).　Conclusion　A combination of immunotherapy and hepatic chemoembolization for liver cancer after radical surgery is an effective treatment, it can reduce the intrahepatic recurrence rate and increase the survival rate.